Enterprise Value
3.981B
Cash
786M
Avg Qtr Burn
-127.1M
Short % of Float
9.64%
Insider Ownership
1.29%
Institutional Own.
-
Qtr Updated
09/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ARIKAYCE (Amikacin Liposome Inhalation Suspension) Details Mycobacterium avium complex lung disease, Nontuberculous mycobacterial lung disease | Approved Update | |
Brensocatib (DPP1 inhibitor) Details Non-Cystic Fibrosis Bronchiectasis | Phase 3 Data readout | |
TPIP (Treprostinil Palmitil Inhalation Powder) Details Pulmonary arterial hypertension | Phase 2 Interim update | |
TPIP (Treprostinil Palmitil Inhalation Powder) Details Pulmonary hypertension | Phase 2 Interim update | |
Brensocatib (DPP1 inhibitor) Details Cystic fibrosis | Phase 2 Update | |
Brensocatib (DPP1 inhibitor) Details Chronic rhinosinusitis | Phase 2 Initiation |